HomeCompareSPYD vs ZBH

SPYD vs ZBH: Dividend Comparison 2026

SPYD yields 4.41% · ZBH yields 1.08%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPYD wins by $5.4K in total portfolio value
10 years
SPYD
SPYD
● Live price
4.41%
Share price
$45.11
Annual div
$1.99
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.7K
Annual income
$584.62
Full SPYD calculator →
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →

Portfolio growth — SPYD vs ZBH

📍 SPYD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPYDZBH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPYD + ZBH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPYD pays
ZBH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPYD
Annual income on $10K today (after 15% tax)
$374.62/yr
After 10yr DRIP, annual income (after tax)
$496.93/yr
ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
At 15% tax rate, SPYD beats the other by $396.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPYD + ZBH for your $10,000?

SPYD: 50%ZBH: 50%
100% ZBH50/50100% SPYD
Portfolio after 10yr
$24.0K
Annual income
$351.63/yr
Blended yield
1.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ZBH right now

SPYD
No analyst data
ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPYD buys
0
ZBH buys
0
No recent congressional trades found for SPYD or ZBH in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPYDZBH
Forward yield4.41%1.08%
Annual dividend / share$1.99$0.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.2%
Portfolio after 10y$26.7K$21.2K
Annual income after 10y$584.62$118.64
Total dividends collected$5.2K$1.1K
Payment frequencyquarterlyquarterly
SectorETFHealthcare

Year-by-year: SPYD vs ZBH ($10,000, DRIP)

YearSPYD PortfolioSPYD Income/yrZBH PortfolioZBH Income/yrGap
1← crossover$11,141$440.73$10,809$108.54+$332.00SPYD
2$12,379$458.88$11,675$109.86+$704.00SPYD
3$13,723$476.54$12,603$111.13+$1.1KSPYD
4$15,177$493.69$13,598$112.34+$1.6KSPYD
5$16,750$510.29$14,663$113.51+$2.1KSPYD
6$18,448$526.32$15,804$114.62+$2.6KSPYD
7$20,281$541.78$17,026$115.69+$3.3KSPYD
8$22,258$556.65$18,335$116.71+$3.9KSPYD
9$24,387$570.93$19,736$117.70+$4.7KSPYD
10$26,678$584.62$21,236$118.64+$5.4KSPYD

SPYD vs ZBH: Complete Analysis 2026

SPYDETF

The State Street SPDR Portfolio S&P 500 High Dividend ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P 500 High Dividend Index (the "Index")A low cost ETF that seeks to provide a high level of dividend income and the opportunity for capital appreciationThe Index is designed to measure the performance of the top 80 high dividend-yielding companies within the S&P 500 IndexOne of the low cost core State Street SPDR Portfolio ETFs, a suite of portfolio building blocks designed to provide broad, diversified exposure to core asset classes

Full SPYD Calculator →

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →
📬

Get this SPYD vs ZBH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPYD vs SCHDSPYD vs JEPISPYD vs OSPYD vs KOSPYD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.